Answers are grounded in this paper and cite their sources.
Prospective trial shows that glipizide improves glycemic control in patients with pancreatic cancer-related diabetes, suggesting clinical benefits.
Introduction and Objective: Pancreatic ductal adenocarcinoma associated diabetes mellitus (PDAC-DM) is a unique paraneoplastic state characterized by insulin deficiency and rapid weight loss. Sulfonylureas may offer targeted benefits in this unique patient population by reversing the paraneoplastic insulin deficiency. This study investigated the safety and effectiveness of sulfonylureas in PDAC-DM. Methods: We conducted a single-arm, prospective trial of extended-release glipizide in adults with hyperglycemia and PDAC (N=20). Primary endpoints were change in mean CGM glucose and symptomatic hypoglycemia. Secondary endpoints included quality of life, metabolic biomarkers, and CT-based volumetric body composition measurements. Results: Glipizide initiation reduced CGM-derived glucose by 40 mg/dL (p=0.019) and HbA1c by 1.5% (p=0.004). HOMA-B increased from 22 to 56 (p=0.042). No severe hypoglycemia occurred, and weight remained stable over 4 months. Global quality of life improved over follow-up, and body composition analyses showed preferential reductions in adipose tissue with relative preservation of skeletal muscle quality. Conclusion: Among patients with active PDAC, glipizide was safe, well tolerated, and associated with improvements in glycemic control, insulin production, and quality of life.
No takes yet. Share an insight, caveat, or question.
Ryan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: